SEC comment letter
SEC correspondence
SEC staff questioned Clinuvel Pharmaceuticals Ltd's accounting for MD&A
Letter dated 2026-03-19; published on EDGAR 2026-09-15 — the SEC releases comment letters only after the review closes.
Please revise to address the following: • Revise the total capitalization amount in the table to reconcile to the balance sheet rather than using market capitalization; • Include a double line underneath the cash and cash equivalents and short-term investments numbers to distinguish them from the capitalization line items; and • Explain what the 'All other assets' line item represents and why it is included in the…
Evidence
- Cited sections
- Item 3. Key Information B. Capitalization and Indebtedness, page 4, Item 4. Information on the Company, page 22, Item 4.B. Business Overview, page 24
- Direction
- staff to company
- Letter dated
- 2026-03-19
- Published on edgar
- 2026-09-15
- Reviewing
- Clinuvel Pharmaceuticals Limited Amendment No. 1 to Draft Registrant Statement on Form 20-F Submitted March 4, 2026 CIK No. 0001290877 Dear Phillipe Wolgen: We
- Source
- SEC staff comment letter (UPLOAD)
- Topics
- MD&A, Revenue recognition
- Why
- SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.